Quark Venture

Sitka Biopharma Inc. is a preclinical biotechnology company based in Vancouver, Canada, established in 2013. The company specializes in developing a nanoparticle platform technology aimed at improving drug absorption in challenging tissues. Its primary focus is on oncology, with its lead candidate, STK-01, designed to enhance the effectiveness of intravesical chemotherapy for bladder cancer. This technology addresses significant issues related to limited drug uptake and tolerability in current treatment options. Sitka's innovative approach seeks to deliver higher concentrations of the chemotherapeutic agent docetaxel directly into the bladder wall, which may lead to better treatment outcomes. The company plans to expand its applications to intraperitoneal delivery for ovarian cancer, demonstrating the versatility of its nanoparticle platform in treating localized diseases effectively.

Canary Medical Inc. specializes in the development of medical implant and data management devices that facilitate remote patient monitoring and data collection. The company's primary innovation is the Canary Health Implantable Reporting Processor (CHIRP), a sensor-based device designed to gather and process medical data without requiring direct physician intervention. Additionally, Canary Medical creates smart medical devices that provide self-reports on patient activity, recovery, and treatment outcomes, thereby enhancing patient compliance. Established in 2013 and headquartered in Vancouver, Canada, the company has also formed a joint venture with BioScience Managers to launch CHARM Informatics, a platform aimed at collecting and monetizing data from implantable and wearable medical devices.

Canary Medical Inc. specializes in the development of medical implant and data management devices that facilitate remote patient monitoring and data collection. The company's primary innovation is the Canary Health Implantable Reporting Processor (CHIRP), a sensor-based device designed to gather and process medical data without requiring direct physician intervention. Additionally, Canary Medical creates smart medical devices that provide self-reports on patient activity, recovery, and treatment outcomes, thereby enhancing patient compliance. Established in 2013 and headquartered in Vancouver, Canada, the company has also formed a joint venture with BioScience Managers to launch CHARM Informatics, a platform aimed at collecting and monetizing data from implantable and wearable medical devices.

ARTMS Products Inc. is a Vancouver-based company that specializes in manufacturing diagnostic imaging systems for the production and separation of medical isotopes. Founded in 2013, the company has developed the QUANTM Irradiation System, which facilitates decentralized and local production of critical isotopes such as gallium-68, zirconium-89, technetium-99m, and copper-64. ARTMS's primary offering, QUANTM99, is a system that combines hardware and consumables for the effective production of technetium-99m using medical cyclotrons. This innovative approach aims to enhance the accessibility and cost-effectiveness of medical isotopes, improving diagnostic imaging services.

Sitka Biopharma Inc. is a preclinical biotechnology company based in Vancouver, Canada, established in 2013. The company specializes in developing a nanoparticle platform technology aimed at improving drug absorption in challenging tissues. Its primary focus is on oncology, with its lead candidate, STK-01, designed to enhance the effectiveness of intravesical chemotherapy for bladder cancer. This technology addresses significant issues related to limited drug uptake and tolerability in current treatment options. Sitka's innovative approach seeks to deliver higher concentrations of the chemotherapeutic agent docetaxel directly into the bladder wall, which may lead to better treatment outcomes. The company plans to expand its applications to intraperitoneal delivery for ovarian cancer, demonstrating the versatility of its nanoparticle platform in treating localized diseases effectively.

PHEMI Systems Corporation specializes in developing a privacy, security, governance, and data management system tailored for Microsoft Azure. Founded in 2013 and based in Vancouver, Canada, the company provides the PHEMI Data Privacy Manager, a cloud-based solution designed for the healthcare sector. This system addresses the critical need for organizations to secure and govern access to privacy-sensitive information while facilitating compliance with privacy regulations. Optimized for Microsoft Azure, the software connects to numerous data sources and integrates seamlessly with popular data science and business analysis tools. Built on a privacy-by-design architecture, PHEMI Data Privacy Manager supports data sharing and offers a flexible usage-based pricing model, making it scalable for organizations of varying sizes.

Microbion Corporation is a biopharmaceutical company dedicated to developing therapeutics for difficult-to-treat infections, particularly those caused by antibiotic-resistant bacteria. Founded in 1982 and headquartered in Bozeman, Montana, with an office in Vancouver, Canada, the company specializes in bismuth-thiols to address chronic and acute wound infections, post-surgical orthopedic infections, and to manage microbial biofilms associated with medical devices. Microbion's products aim to prevent microbial biofilms from forming on implanted devices and are designed to treat conditions such as diabetic foot ulcers and orthopedic implant-related infections. Additionally, the company focuses on reducing infections associated with military wounds.

MSI Methylation Sciences Inc. is a biotechnology company based in Canada that focuses on developing oral and small molecule therapies for the adjunctive treatment of Major Depressive Disorder (MDD). Founded in 2007, the company is known for its flagship product, Strada, which is an orally administered therapy aimed at alleviating symptoms of depression in MDD patients. In addition to its therapeutic developments, MSI Methylation Sciences also markets S-Adenosyl Methionine, a prescription drug used as a dietary supplement. The company's work is centered around addressing mental health challenges through innovative treatment options.

Sitka Biopharma Inc. is a preclinical biotechnology company based in Vancouver, Canada, established in 2013. The company specializes in developing a nanoparticle platform technology aimed at improving drug absorption in challenging tissues. Its primary focus is on oncology, with its lead candidate, STK-01, designed to enhance the effectiveness of intravesical chemotherapy for bladder cancer. This technology addresses significant issues related to limited drug uptake and tolerability in current treatment options. Sitka's innovative approach seeks to deliver higher concentrations of the chemotherapeutic agent docetaxel directly into the bladder wall, which may lead to better treatment outcomes. The company plans to expand its applications to intraperitoneal delivery for ovarian cancer, demonstrating the versatility of its nanoparticle platform in treating localized diseases effectively.